Loading stock…

Ingevity Corporation (NGVT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Ingevity Corporation

NGVTMarket cap $2.50BPrice $72.8

Country🇺🇸United States

SectorMaterials

IndustryChemicals

Makes specialty chemicals from pine trees, turning refined tree resin into everything from asphalt additives to fragrances. Its activated carbon also captures gasoline vapors in your car's emissions system — most drivers have no idea it's there.

In Bastion Portfolios?

52W Return+34%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-11%1

Revenue Forecast

Rev CAGR (1y)-5%1

Rev CAGR (3y)-0%1

Rev CAGR (5y)+16%9

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+13%7

EPS Growth Y+3+6%5

Quality

Margins

EBIT Margin25%8

Net Income Margin5%3

Free Cash Flow Margin13%7

Debt

Net Debt/EBITDA2.93

Efficiency

ROE30%9

ROA3%5

Earnings Stability44

GEAR+WEAK33

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)137

P/E Ratio (Forward 3y)127

P/BV53.41

EV Multiples

EV/EBITDA Fwd97

EV/EBIT Fwd127

Yield

Free Cash Flow Yield6.2%7

Dividend Yieldna–

Momentum

Short term

1 month return+3%9

3 month return-1%6

YTD return+23%8

Mid term

Price vs 52wHigh92%8

1 year return+36%8

Long term

3 year return+72%7

5 year return-4%3

Risk Shield

Price Risk

Beta1.42

Volatility36%5

Free Cash Flow

Free Cash Flow Margin13%7

Free Cash Flow Yield6.2%7

Quality

ROCE21%9

Earnings Stability44

Net Debt/EBITDA2.93

02Growth

Is it actually growing, and how fast?

NGVTIngevity

Revenue FY25$1.2B

GROWTH RATING↗

WEAK25 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-11%1

Revenue, next 1Y-5%1

Revenue, next 3Y, CAGR-0%1

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+13%7

EPS growth, FY28E+6%5

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 6%/yr vs revenue -0.4%/yr), so margins should widen.

WATCH

Revenue is set to hold flat over the next 3 years, a little behind the market.4/10

Revenue fell 11%/yr over the last 3 years, and it is still set to hold flat.

WEAKNESSES

Growth is the weak spot here, trailing 75% of companies worldwide.

Revenue fell 11%/yr over the last 3 years, behind 90% of companies worldwide.1/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business whose decline is easing. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+3%9

3-month return-1%6

YTD return+23%8

MID & LONG-TERM▾SCORE

% of 52-week high92%8

1-year return+36%8

3-year return+72%7

5-year return-4%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 36% over the past year, but 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+3%) and so far this year (+23%).

WATCH

Average long-term results. Multi-year returns are middling (+72% over three years and -3.9% over five), roughly average for the market.

Returns sit at the market level over three months (-1%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Ingevity Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

NGVTIngevity

Revenue FY25$1.2B

GROWTH RATING↗

WEAK25 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-11%1

Revenue, next 1Y-5%1

Revenue, next 3Y, CAGR-0%1

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+13%7

EPS growth, FY28E+6%5

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 6%/yr vs revenue -0.4%/yr), so margins should widen.

WATCH

Revenue is set to hold flat over the next 3 years, a little behind the market.4/10

Revenue fell 11%/yr over the last 3 years, and it is still set to hold flat.

WEAKNESSES

Growth is the weak spot here, trailing 75% of companies worldwide.

Revenue fell 11%/yr over the last 3 years, behind 90% of companies worldwide.1/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business whose decline is easing. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+3%9

3-month return-1%6

YTD return+23%8

MID & LONG-TERM▾SCORE

% of 52-week high92%8

1-year return+36%8

3-year return+72%7

5-year return-4%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 36% over the past year, but 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+3%) and so far this year (+23%).

WATCH

Average long-term results. Multi-year returns are middling (+72% over three years and -3.9% over five), roughly average for the market.

Returns sit at the market level over three months (-1%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Ingevity Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community